Protagonist Therapeutics, Inc. PTGX
Set alert
139.37 USD -5.48 -3.78%
At close · Nov 2
139.37 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
139.35 Day range 146.01
75.44 52-week range 160.81
- YTD
- +59.57%
- 1 year
- +77.27%
- Open
- 145.74
- Prev close
- 144.85
- Mkt cap
- 9.02B
- Vol
- 486.51K
- Avg vol
- 645.05K
- EPS
- 1.03
- P/E
- 135.31
- Div yield
- 0.00%
More statistics
- Low
- 139.35
- High
- 146.01
- Forward P/E
- -1404.09
- Beta
- 1.22
- Short ratio
- 12.29
- Inst. own
- 119.68%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 142.93
- 200-d avg
- 116.62
- 1y target
- 178.57
2Y chart
Events in this range
- Aug 6, 2025Earnings: -0.55; estimate -0.53; surprise -3.77%
- Nov 6, 2025Earnings: -0.62; estimate -0.59; surprise -5.08%
- Feb 25, 2026Earnings: -0.69; estimate -0.53; surprise -30.19%
- May 5, 2026Earnings: 0.05; estimate -0.65; surprise 107.69%
- Aug 5, 2026Earnings: 2.29; estimate 2.23; surprise 2.69%
- Aug 31, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Aug 31, 2026Rating: Citigroup · Buy → Buy
- Sep 1, 2026Rating: BMO Capital · Outperform → Outperform
- Sep 1, 2026Rating: Barclays · Overweight → Overweight
- Oct 12, 2026Rating: UBS · — → Buy
- Oct 21, 2026Rating: TD Cowen · Buy → Buy
Signals (88)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 2026 | 8 hours ago |
| SMA: Bullish | Oct 29, 2026 | 4 days ago |
| MACD: Buy Signal | Oct 22, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 24, 2026 | 2 months ago |
| RSI: Overbought | Aug 14, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 15, 2026 | 3 months ago |
| RSI: Overbought | Jun 24, 2026 | 4 months ago |
| SMA: Bullish | Jun 9, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 9, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 5 months ago |
| SMA: Bullish | Jun 4, 2026 | 5 months ago |
| SMA: Bearish | May 28, 2026 | 5 months ago |
| SMA: Bullish | May 27, 2026 | 5 months ago |
| SMA: Bearish | May 22, 2026 | 5 months ago |
| SMA: Bullish | May 21, 2026 | 5 months ago |
| MACD: Sell Signal | May 19, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| SMA: Bullish | May 13, 2026 | 5 months ago |
| MACD: Buy Signal | May 13, 2026 | 5 months ago |
| SMA: Bearish | May 12, 2026 | 5 months ago |
| SMA: Bullish | May 11, 2026 | 5 months ago |
| SMA: Bearish | May 7, 2026 | 5 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| SMA: Bearish | May 1, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 6, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 31, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 30, 2026 | 7 months ago |
| RSI: Overbought | Mar 2, 2026 | 8 months ago |
| SMA: Bullish | Feb 23, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 3, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 28, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 22, 2026 | 9 months ago |
| SMA: Bearish | Jan 5, 2026 | 10 months ago |
| MACD: Sell Signal | Dec 17, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 12, 2025 | 10 months ago |
| RSI: Overbought | Dec 12, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 1, 2025 | 11 months ago |
| RSI: Overbought | Nov 25, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 24, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 20, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 10, 2025 | 11 months ago |
| MACD: Sell Signal | Oct 22, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 10, 2025 | 1 year ago |
| RSI: Overbought | Oct 10, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 6, 2025 | 1 year ago |
| RSI: Overbought | Sep 26, 2025 | 1 year ago |
| RSI: Overbought | Sep 24, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 18, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 8, 2025 | 1 year ago |
| RSI: Overbought | Aug 27, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 13, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
| SMA: Bearish | Aug 7, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 29, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 28, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 24, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 15, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 20, 2025 | 1 year ago |
| RSI: Overbought | Jun 5, 2025 | 1 year ago |
| SMA: Bullish | May 29, 2025 | 1 year ago |
| SMA: Bearish | May 28, 2025 | 1 year ago |
| SMA: Bullish | May 27, 2025 | 1 year ago |
| MACD: Buy Signal | May 15, 2025 | 1 year ago |
| MACD: Sell Signal | May 5, 2025 | 1 year ago |
| SMA: Bearish | May 1, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 30, 2025 | 1 year ago |
| SMA: Bullish | Apr 29, 2025 | 1 year ago |
| SMA: Bearish | Apr 24, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 24, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 23, 2025 | 1 year ago |
| SMA: Bullish | Apr 14, 2025 | 1 year ago |
| SMA: Bearish | Apr 7, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 25, 2025 | 1 year ago |
| RSI: Overbought | Mar 10, 2025 | 1 year ago |
| SMA: Bullish | Mar 3, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 3, 2025 | 1 year ago |
| SMA: Bearish | Feb 24, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 24, 2025 | 1 year ago |
| SMA: Bullish | Feb 21, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 21, 2025 | 1 year ago |
Key statistics
- Market cap
- 9.02B
- Enterprise value
- 8.60B
- Trailing P/E
- 135.31
- Forward P/E
- -1404.09
- PEG ratio
- 0.00
- Price / sales
- 31.98
- Price / book
- 10.71
- EPS (TTM)
- 1.03
- Beta
- 1.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 29.40%
- Revenue (TTM)
- 281.99M
- Revenue growth
- 3749.20%
- Free cash flow
- 96.15M
- Total cash
- 782.58M
- Total debt
- 9.22M
- Return on equity
- 10.98%
- Shares outstanding
- 64.71M
- Short % of float
- 18.49%
- 50-day average
- 142.93
- 200-day average
- 116.62
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 178.57 +28.1% upside
Now 139.37
- Target (low)
- 149.00
- Target (mean)
- 178.57
- Target (high)
- 225.00
Ratings (0m) 14 14 buy · 0 hold · 0 sell
- Strong buy3
- Buy11
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 2.66.
Financials — quick view
PTGX Revenue — quarterly 213.47M
PTGX Net income — quarterly 162.85M
PTGX EPS — quarterly 2.47
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 2.50 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | 2.23 | 2.29 | +0.06 | +2.69% |
| May 5, 2026 | Mar 31, 2026 | -0.65 | 0.05 | +0.70 | +107.69% |
| Feb 25, 2026 | Dec 31, 2025 | -0.53 | -0.69 | -0.16 | -30.19% |
| Nov 6, 2025 | Sep 30, 2025 | -0.59 | -0.62 | -0.03 | -5.08% |
| Aug 6, 2025 | Jun 30, 2025 | -0.53 | -0.55 | -0.02 | -3.77% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 21, 2026 | TD Cowen | main | Buy | Buy |
| Oct 12, 2026 | UBS | init | — | Buy |
| Sep 1, 2026 | Barclays | main | Overweight | Overweight |
| Sep 1, 2026 | BMO Capital | main | Outperform | Outperform |
| Aug 31, 2026 | Citigroup | main | Buy | Buy |
| Aug 31, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- protagonist-inc.com
News
- Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth
- Why Protagonist Therapeutics (PTGX) is a Top Momentum Stock for the Long-Term
- Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?
- Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty Compounder
- TD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $160
- Analyzing Protagonist Therapeutics (NASDAQ:PTGX) and Sarepta Therapeutics (NASDAQ:SRPT)
- Head to Head Review: Genelux (NASDAQ:GNLX) versus Protagonist Therapeutics (NASDAQ:PTGX)
- Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know
- Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth Today
- UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184
Your note
Sign in to keep a note on PTGX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALI ASIF | Chief Financial Officer | Sale | Apr 19, 2026 | 59,003 |
| GIRAUDO BRYAN M. | Director | Sale | May 7, 2026 | 0 |
| GUPTA SUNEEL | Officer | Conversion of Exercise of derivative security | Nov 25, 2024 | 267,433 |
| MOLINA ARTURO MD | Officer | Conversion of Exercise of derivative security | Mar 25, 2026 | 84,115 |
| O DOWD SARAH A | Director | Stock Award(Grant) | Jan 1, 2026 | 7,825 |
| PATEL DINESH V | Chief Executive Officer | Conversion of Exercise of derivative security | Sep 9, 2026 | 522,968 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 15.93% | 10,307,837 | 1.44B | Jun 29, 2026 |
| Farallon Capital Management LLC | 9.81% | 6,348,906 | 884.85M | Jun 29, 2026 |
| RTW Investments LP | 7.82% | 5,061,175 | 705.38M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.61% | 3,629,298 | 505.82M | Jun 29, 2026 |
| Wellington Management Group, LLP | 5.28% | 3,416,781 | 476.20M | Jun 29, 2026 |
| UBS Group AG | 5.25% | 3,399,221 | 473.75M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.96% | 3,854,840 | 537.25M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.16% | 2,044,938 | 285.00M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.46% | 1,594,175 | 222.18M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.28% | 1,475,422 | 205.63M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.92% | 1,243,618 | 173.32M | Jul 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.57% | 1,013,552 | 141.26M | Sep 29, 2026 |